Baveno VIII – Advancing consensus in portal hypertension
Abstract
Since the first Baveno Consensus Conference in 1990, successive conferences held every 5 years have transformed the field of cirrhosis and portal hypertension, evolving from a focus on variceal bleeding to a pathophysiology-based framework centred on risk stratification, clinically significant portal hypertension (CSPH), and the prevention of decompensation. Building on this progress, the Baveno Cooperation, in collaboration with the Vascular Liver Disease Interest Group (VALDIG), convened an expert faculty to review the evidence published since Baveno VII and update clinical guidance for patients with advanced chronic liver disease (ACLD), portal hypertension, and vascular liver diseases. The Baveno VIII Consensus Conference, held in March 2026 in Baveno, Italy, was based on a structured consensus process across nine panels addressing key domains of ACLD, portal hypertension, and vascular liver diseases. Statements and recommendations were developed through iterative review of the evidence and voting among faculty, with strong consensus defined as >80% faculty agreement. A total of 272 statements and recommendations achieved strong consensus. Key areas included non-invasive risk stratification in compensated ACLD (cACLD), modifiers of steatotic liver disease, prevention of first and further decompensation, management of portal hypertensive bleeding and further decompensation, cirrhosis recompensation, and vascular liver diseases, including Budd-Chiari syndrome, portosinusoidal vascular disorder (PSVD) or non-cirrhotic portal fibrosis (NCPF), and portal vein thrombosis (PVT). The central role of CSPH and the expanding use of non-invasive tests were reaffirmed, and several diagnostic and prognostic cut-offs were revised. New to Baveno VIII is the inclusion of selected guidance for paediatric patients. Recommendations from previous conferences that were not specifically revised in Baveno VIII, such as those on hepatic venous pressure gradient (HVPG) measurement, remain valid. Finally, a research agenda identifying 153 priority topics is proposed.
Related
- Chinese consensus on the management of pancreatic portal hypertension
- Biopsy-Proven Hepatic Extramedullary Hematopoiesis With Chronic Portal Vein Thrombosis in JAK2 V617F-Positive Prefibrotic Myelofibrosis: Contributors to Noncirrhotic Portal Hypertension
- Proximal Splenorenal Shunt in Non-cirrhotic Portal Hypertension: Our Experience
- Case Report: Early-onset portal hypertension revealing pediatric ADPKD with a truncating PKD1 variant
- Endoscopic ultrasound-guided selective inflow vessel devascularization and multi-point venous occlusion for gastric varices due to left-sided portal hypertension.
BibTeX
@article{berzigotti2026baveno,
title = {{Baveno VIII – Advancing consensus in portal hypertension}},
author = {Annalisa Berzigotti and Mattias Mandorfer and Mònica Pons and Juan G. Abraldeṣ and Elton Dajti and Joan Genescà and Mathias Jachs and Tassos Grammatikopoulos and Emmanuel A. Tsochatzis and Sven Francque and Laurent Castéra and Alina M. Allen and Alexandre LOUVET and Vincent Wai‐Sun Wong and Cristina RIPOLL and Jaime Bosch and Rafael Bañares and Dhiraj Tripathi and Vincenza Calvaruso and Càndid Villanueva and José Ignacio Fortea and Vishal Patel and Susana Gomes Rodrigues and Vincenzo La Mura and Christophe Bureau and Anahita Rabiee and Gennaro D’Amico and Puneeta Tandon and Laura Turco and Manon Allaire and Florent Artru and Jonel Trebicka and Alexander Zipprich and Marika Rudler and Juan Carlos García‐Pagán and Wim Laleman and Bogdan Procopeț and Charlotte Bouzbib and Brett E. Fortune and Ron Charles Gaba and Anna Baiges and Filippo Schepis and Xuefeng LUO and Ian Mark Gralnek and Dominique Thabut and Salvatore Silvio Piano and Paolo CARACENI and Benjamin Maasoumy and Agustín Albillos and Dominik Bettinger and Francesco Vizzutti and Jasmohan S. Bajaj and Hélène Larrue and Rakhi Maiwall and Guadalupe GARCIA-TSAO and Thomas Reiberger and Jidong JIA and Douglas Alano Simonetto and Georg Semmler and Elisa Pose},
journal = {Journal of Hepatology},
year = {2026},
month = aug,
doi = {10.1016/j.jhep.2026.07.030},
url = {https://doi.org/10.1016/j.jhep.2026.07.030},
note = {CC BY},
}
RIS
TY - JOUR
TI - Baveno VIII – Advancing consensus in portal hypertension
AU - Annalisa Berzigotti
AU - Mattias Mandorfer
AU - Mònica Pons
AU - Juan G. Abraldeṣ
AU - Elton Dajti
AU - Joan Genescà
AU - Mathias Jachs
AU - Tassos Grammatikopoulos
AU - Emmanuel A. Tsochatzis
AU - Sven Francque
AU - Laurent Castéra
AU - Alina M. Allen
AU - Alexandre LOUVET
AU - Vincent Wai‐Sun Wong
AU - Cristina RIPOLL
AU - Jaime Bosch
AU - Rafael Bañares
AU - Dhiraj Tripathi
AU - Vincenza Calvaruso
AU - Càndid Villanueva
AU - José Ignacio Fortea
AU - Vishal Patel
AU - Susana Gomes Rodrigues
AU - Vincenzo La Mura
AU - Christophe Bureau
AU - Anahita Rabiee
AU - Gennaro D’Amico
AU - Puneeta Tandon
AU - Laura Turco
AU - Manon Allaire
AU - Florent Artru
AU - Jonel Trebicka
AU - Alexander Zipprich
AU - Marika Rudler
AU - Juan Carlos García‐Pagán
AU - Wim Laleman
AU - Bogdan Procopeț
AU - Charlotte Bouzbib
AU - Brett E. Fortune
AU - Ron Charles Gaba
AU - Anna Baiges
AU - Filippo Schepis
AU - Xuefeng LUO
AU - Ian Mark Gralnek
AU - Dominique Thabut
AU - Salvatore Silvio Piano
AU - Paolo CARACENI
AU - Benjamin Maasoumy
AU - Agustín Albillos
AU - Dominik Bettinger
AU - Francesco Vizzutti
AU - Jasmohan S. Bajaj
AU - Hélène Larrue
AU - Rakhi Maiwall
AU - Guadalupe GARCIA-TSAO
AU - Thomas Reiberger
AU - Jidong JIA
AU - Douglas Alano Simonetto
AU - Georg Semmler
AU - Elisa Pose
PY - 2026
DA - 2026/08/20
JO - Journal of Hepatology
DO - 10.1016/j.jhep.2026.07.030
UR - https://doi.org/10.1016/j.jhep.2026.07.030
AB - Since the first Baveno Consensus Conference in 1990, successive conferences held every 5 years have transformed the field of cirrhosis and portal hypertension, evolving from a focus on variceal bleeding to a pathophysiology-based framework centred on risk stratification, clinically significant portal hypertension (CSPH), and the prevention of decompensation. Building on this progress, the Baveno Cooperation, in collaboration with the Vascular Liver Disease Interest Group (VALDIG), convened an expert faculty to review the evidence published since Baveno VII and update clinical guidance for patients with advanced chronic liver disease (ACLD), portal hypertension, and vascular liver diseases. The Baveno VIII Consensus Conference, held in March 2026 in Baveno, Italy, was based on a structured consensus process across nine panels addressing key domains of ACLD, portal hypertension, and vascular liver diseases. Statements and recommendations were developed through iterative review of the evidence and voting among faculty, with strong consensus defined as >80% faculty agreement. A total of 272 statements and recommendations achieved strong consensus. Key areas included non-invasive risk stratification in compensated ACLD (cACLD), modifiers of steatotic liver disease, prevention of first and further decompensation, management of portal hypertensive bleeding and further decompensation, cirrhosis recompensation, and vascular liver diseases, including Budd-Chiari syndrome, portosinusoidal vascular disorder (PSVD) or non-cirrhotic portal fibrosis (NCPF), and portal vein thrombosis (PVT). The central role of CSPH and the expanding use of non-invasive tests were reaffirmed, and several diagnostic and prognostic cut-offs were revised. New to Baveno VIII is the inclusion of selected guidance for paediatric patients. Recommendations from previous conferences that were not specifically revised in Baveno VIII, such as those on hepatic venous pressure gradient (HVPG) measurement, remain valid. Finally, a research agenda identifying 153 priority topics is proposed.
SN - 0168-8278
SN - 1600-0641
ER -